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ABSTRACT
Human cartilage contains multipotent stem cells, namely mesenchymal stem cells (MSCs) which are progenitors of 
connective tissue that play homeostatic and reparative roles. Although the major constituent cells in the cartilage are 
chondrocytes, they possess a limited regenerative ability, and as a result, spontaneous cartilage repair by chondro-
cytes leads to the synthesis of fibrocartilage. Similarly, MSCs derived from articular cartilage of osteoarthritis patients 
have demonstrated inadequacy in cartilage repair. The role of MSCs in the pathophysiology of osteoarthritis (OA) is 
not entirely understood, whether the inflammatory milieu associated with OA joints affects the reparative properties 
of MSCs or the inherent defects of OA cartilage-derived MSCs impair the proper execution of the required immu-
nosuppressive and reparative functions. Therefore, the current review explores the biological characteristics and 
features of MSCs derived from physiological state and OA condition with the aim of identifying how OA affects MSC 
functions as well as the role of MSCs in the pathophysiology of OA.
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INTRODUCTION
The familiar form of arthritis is osteoarthritis (OA). It is 
a disease that results in the degradation of joint tissue, 
and associated with severe pain and causes disability in 
adults (1). The OA involves the action of inflammatory 
mediators at the joint resulting in an irregular remodelling 
of the joint tissues (2). There are several risk factors 
associated with OA; however, obesity, age, gender, 
prior joint injury, and genetic history are among the most 
important ones (3). Although OA has been identified 
as a complex condition with a very obscure aetiology, 
the damage or loss of articular cartilage accompanied 
by changes in the subchondral bone with synovial 
inflammation being the consistent element that defines 
the disease (4). Synovial inflammation can disturb joint 
homeostasis (5), and it has been linked with pain and 
the progression of OA disease (6). The main cellular 
components of cartilage tissue are the chondrocytes 
which are inert cells with limited regenerative capacity 
(7). Consequent of the poor replicative capability of 
chondrocytes, different treatment approaches have been 
developed over the last decade, most noticeable of which 
is the autologous chondrocyte transplantation (ACT) (8). 
The ACT involves isolation of chondrocytes from the 
cartilage tissue biopsy obtained from the patient. These 
chondrocytes are then expanded and administered into 
the patient to fill the cartilage defect (9). Although ACT 
has recorded impressive clinical results, the surgical 
technique is being faced with significant setbacks 
resulting primarily from the phenomenon of chondrocyte 
de-differentiation where the infused chondrocytes on 
exposure to  inflammatory factors during the expansion 
phase, lose their phenotype and hence their ability to 
synthesize extracellular matrix (ECM) molecules such as 
COL II and aggrecan (8, 10). For this reason, researchers 
are considering mesenchymal stem cells (MSCs) as 
a potential alternative cell source for cartilage tissue 
regeneration (11).
MSCS AND THEIR CHARACTERISTICS IN OA
Resident MSCs populations have been found in 
the cartilage tissue, synovium and synovial fluid of 
healthy (non-OA) individuals. As compared to the BM-
MSCS, cartilage-derived MSCs are able to differentiate 
into cartilage, fat, bone and muscle tissues coupled 
with potent immunomodulatory prowess, injury/
inflammation-triggered migration as well as secretion of 
various soluble factors. Cartilage-derived MSCs reside 
at the joint area to serve in the maintenance of  tissue 
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homeostasis and exert tissue reparative functions in 
response to tissue damage resulting from mechanical 
injury and/or degenerative diseases (12). 
However, the ability of MSCs to execute their 
physiological function can be affected by non-age 
related factors. Specifically, MSCs isolated from arthritic 
tissues have exhibited some form of deficiency in 
biological characteristics such as proliferation rate, 
differentiation potential as well as immunosuppressive 
prowess, when compared to those from healthy tissues 
(13). Global gene profiling and microRNA studies have 
identified differentially regulated genes involved in 
bone metabolism (14) as well as the difference in the 
levels of microRNAs that are related to osteogenesis 
(15) in OA-MSCs when compared to non-OAMSCs, 
supporting the opinion that nearly all diseases have 
genetic aetiology (16).  Low proliferative capacity, 
reduced chondrogenesis and poor immunosuppressive 
ability have been reported in MSCs derived from OA 
tissues. Table I highlights the changes observed in some 
biological characteristics of OA-MSCs concerning 
healthy MSCs as reported by previous studies.
CARTILAGE-DERIVED MESENCHYMAL STEM CELLS 
The first isolation of multipotent MSCs from joint 
tissue was conducted in 2001 (20). The MSCs were 
isolated from the synovial membrane of a healthy adult 
human by enzymatic digestion technique. These cells 
showed the capacity for osteogenesis, chondrogenesis 
and adipogenesis when subjected to the conducive 
stimulants (20). Clonal heterogeneity has been reported 
in MSCs derived from the synovium obtained from 
healthy adult humans as well as from those with a 
history of OA. Their adherent cells show a distinct 
proliferative and differentiation capacity (21). Also, 
MSCs derived from the synovium appeared to show to 
a higher chondrogenic potential when compared with 
cells derived from the bone marrow (BM) or Hoffa’s fat 
pad (22). Interestingly, the synovial fluid of non-OA and 
OA patients are not abundant but potential sources of 
MSCs with the cells showing greater clonogenicity and 
chondrogenic differentiation capacity relative to BM-
MSCs (23).
Many research groups have successfully isolated MSCs 
from cartilage tissue and have recorded similar patterns 
of the proliferation rate, multipotential differentiation, 
clonogenicity and expression of cell surface markers that 
similar to the other sources of MSCs. Su et al. reported 
that the morphology, phenotype and differentiation 
capacity of cartilage-derived stromal cells adheres to 
the standard minimal definition for MSCs (24, 25). In 
one of the elegant studies, Peng et al. had delineated 
that MSCs generated from the cartilage tissue exhibited 
a superior ability of chondrogenesis through cartilage 
matrix formation when compared to the BM-MSCs and 
adipose tissue-derived MSCs (26). Table II highlights 
Table I: Biological characteristics of MSCs from OA and non-OA from 
different sources
No Biological 
characteristic
Tissue 
source
(OA-MSCs)
Tissue source 
(non-OA 
MSCs)
Outcome in OA-
MSCs
1 Cell number 
(yield)
Synovial 
fluid
Synovial fluid 
& Synovium
Increased in cell 
number noted with 
the severity of OA 
(14)
Cartilage Cartilage Reduced percent-
age of cell fraction 
(15)
2 Morphology Synovial 
fluid
Bone marrow Minute variation in 
cell morphology. 
Slightly deviating 
the typical spindle 
shape  (14)
3 Chondrogenic 
differentiation
Bone mar-
row
Bone marrow Reduced chondro-
genic ability (17)
4 Osteogenic 
differentiation
Cartilage Cartilage Enhanced osteo-
geneic differentia-
tion (15)
5 Adipogenic 
differentiation
Bone mar-
row
Bone marrow Reduced adipogen-
ic differentiation 
(17)
Cartilage Cartilage  Weaker adipoge-
neic differentiation 
(15)  
6 Proliferative  
capacity
Bone mar-
row
Bone marrow Lower proliferative 
capability (17, 18)
Cartilage Cartilage Reduced prolifera-
tive ability (15)  
7 Immunosup-
pression
Adipose 
tissue
Adipose 
tissue
Reduced T-cell 
immunosuppression 
(19)
8 MicroRNA 
expression
Cartilage Cartilage Downregulation of 
mir-31-5p & mir-
424-5p (related to 
osteogenesis) (15)   
9 Gene profile Cartilage Cartilage Upregulation of 
osteogenic key 
transcription factor 
RUNX2 (15)  
Synovial 
fluid
Bone marrow Upregulation of 
bone metabolism 
genes 
(with SMOC2, 
GPR133 & SFRP4 
confirmed by RT 
PCR) (14)
differences in the chondrogenic differentiation abilities 
of MSCs derived from various sources as reported by 
previous studies.
Generally bone marrow MSCs showed superior 
chondrogenic potential relative to MSCs derived from 
adipose tissues, muscle and synovium (Table II). On 
the other hand, Shirasawa S. et al., 2016, showed 
that MSCs derived from synovium exhibited a greater 
chondrogenic potential as compared to the bone 
marrow origin which could be attributed to the other 
confounding factor such as age, inflammation and the 
cellular fraction of the tissue origin (22).      However, 
cartilage derived MSCs displayed a higher chondrogenic 
competitive advantage over the bone marrow-derived 
cells. Additionally, Somoza et al. identified what they 
referred to as “molecular phenotype of superior quality” 
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the understanding of the origin of articular cartilage 
tissue-resident MSCs. The initial thought that the 
articular cartilage is formed from epiphyseal cartilage 
that survived endochondral ossification and hence, they 
contain MSCs is no longer applicable (31).  Similarly, 
the idea that cartilage tissue regeneration occurs from 
the deep zone outward has become obsolete (32). 
Recent studies have now shown that chondrocyte 
turnover in the articular cartilage is appositional and not 
interstitial, i.e. it occurs from the superficial zone rather 
than the deep zone (33), and this explains the presence 
of MSC-like resident population in the superficial zone 
(34). Also, the damage of the articular cartilage in early 
chondrogenic OA occurs at the superficial zone (33); 
thus, the MSC population may be located therein to 
function as a source of chondrocyte replenishment. 
Figure 1 illustrates the appositional direction of 
chondrocyte differentiation lineage that leads to the 
formation and regeneration of the articular cartilage.
Although techniques have been developed and 
optimized to maximize the yield of MSCs isolated from 
OA cartilage tissue (35) the unavailability of specific 
markers for C-MSCs has hindered detailed understanding 
of their putative roles cartilage tissue homeostasis. 
Additionally, OA and non-OA C-MSCs have shown 
remarkable ability to undergo long-range migration 
(culture-expanded cells derived from the cartilage of 
patients with OA (>1 mm) in vitro  (36) suggesting that 
this superficial zone cartilage-resident cells may have 
originated from the joint cavity.
Table II: Comparison of chondrogenic differentiation of MSCs from 
different sources
No Sources of MSCs 
compared
Source with supe-
rior chondrogenic 
ability
Competitive advantage
1 Bone marrow & 
Adipose tissue
Bone marrow More extensive staining in 
aggregates formed
Higher proteoglycan deposi-
tion (27)
2 Bone marrow, 
Synovium, 
Adipose tissue & 
Muscle
Bone marrow Produced more cartilage 
matrix  (28)
3 Bone marrow & 
Synovium
Synovium Formed larger and heavier 
cartilage pellets (22).
4 Bone marrow & 
Cartilage
Cartilage Median chondrogenic capac-
ity above bone marrow by 
2-5 fold (29)
5 Bone marrow, 
Cartilage & 
Adipose tissue 
Cartilage Formed more cartilage 
pellets in both induced and 
non-induced group
Shorter time to reach maxi-
mum mRNA expression lev-
els of chondrogenic markers 
COL II & Aggrecan (26).
in cartilage synthesised from human neonatal articular 
cartilage derived MSCs (hNAC-MSCs) compared to 
those synthesized from BM-MSCs (30), suggesting that 
human cartilage-derived MSCs (C-MSC) could be the 
ideal source for cartilage tissue engineering.
Exploring the structural biology of the cartilage tissue 
holds the key to identifying the availability, characteristics 
and function of C-MSCs as there is a paradigm shift in 
Figure 1: The appositional direction of articular cartilage growth. The growth of articular cartilage is achieved by apposition from the articular 
surface where undifferentiated progenitor/ stem cells reside and begin to divide. These committed cells differentiate into chondroblasts that secrete 
cartilage matrix materials. Due to matrix formation, the chondroblasts move apart and develop into chondrocytes which proliferate, secrete more 
matrix and form new cartilage. Thus, new cartilage results from the addition of matrix secreting chondroblasts to the surface by from the inner 
layer of the perichondrium. The chondrocytes mature at the radial zone, leading to calcification and formation of bone tissues. Compiled using 
information sourced from (33, 34).
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MECHANISM OF MSC-MEDIATED TISSUE 
REGENERATION
In recent years, research in translational medicine has 
focused on the application of MSCs in the development 
of therapeutic interventions for the treatment of various 
diseases (37). Although some controversies regarding 
the primary effect of the cells on an injured environment 
still exist, many data suggested that therapeutic 
potential of these cells can be ascribed to paracrine and 
immunomodulatory influence resulting to the production 
of factors that support host cell survival by modulating 
the immune response. These factors also stimulate 
endogenous tissue precursor cells which reside in the 
site of injury to undergo mitosis while simultaneously 
trigger an angiogenic response and prevent abnormal 
fibrotic response (38). 
Inflammation is a putative mediator of tissue injuries, 
and chronic inflammation contributes significantly to 
the many degenerative diseases such as OA and cancers. 
Naturally, MSCs do not provoke the activation of T-cells, 
as they do not express major histocompatibility complex 
class II (MHC II), molecules that present antigen to the 
T helper cells (39). However, injured tissues such as 
inflamed joints in OA, always result in the stimulation 
of immune cells namely,  B cells, CD8+ T cells, CD4+ 
T cells, neutrophils and macrophages (40). On the other 
hand, injured cells can spill their intracellular contents, 
thereby triggering phagocytes to produce inflammatory 
mediators like free radicals, IL-1β, TNF-α and other 
chemokines (41). The localization of immune cells, 
coupled with the accumulation of the inflammatory 
mediators, creates an inflammatory microenvironment 
that induces the migration of MSCs to the site of injury 
(42). Cartilage tissue injuries are mostly inflammatory 
mediated, and such an inflammatory milieu serve as 
an ideal trigger of MSCs’ immunosuppressive and 
regenerative functions (43). This is evident from the 
discovery that therapeutically infused MSCs migrate to 
the site of inflammation, and such migration is probably 
as a result of the upregulation of chemokine receptors 
on MSCs by the inflammatory factors and chemokines 
produced by the injured chondrocytes (44). Figure 2 
schematically shows the mechanism of  MSC-mediated 
chondrocyte replenishment.  
MESENCHYMAL STEM CELLS, INFLAMMATORY 
CYTOKINES AND PARACRINE FACTORS
During the migration, MSCs enter the tissue-specific 
microenvironment of injured cartilage tissue, exert 
paracrine interaction by releasing many soluble factors 
that include growth factors, cytokines and other 
proteins. Growth factors such as angiopoietin-1 (Ang-1), 
transforming growth factor-b (TGF-b), epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF), 
hepatocyte growth factor (HGF), fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), insulin 
growth factor-1 (IGF-1), keratinocyte growth factor 
(KGF) and stromal cell-derived factor-1 (SDF-1) released 
by MSCs are crucial elements in mediating tissue repair 
and regeneration (31, 45). Although cartilage contains 
a small pool of tissue-resident stem cells that resemble 
MSCs, extensive tissue damage and non-conducive 
microenvironment in the inflamed synovium hinder 
the execution of tissue-resident stem cells. However, it 
could be possible that the locally injected MSCs or MSCs 
migrated from bone marrow during the inflammation 
enhance the repair and regeneration of cartilage by 
secreting an array of aforementioned growth factors. 
The growth factors induce tissue regeneration and repair 
Figure 2: Mechanism of MSC-mediat-
ed chondrocyte replenishment. The 
MSCs in circulation are stimulated to 
migrate to the injured cartilage by the 
inflammatory cytokines (TNF-α, Tu-
mour Necrotic Factor-alpha; IL-1α/β, 
Interleukin-1alpha/ beta and IFN-γ, In-
terferon-gamma) secreted by immune 
cells (T cells, B cells and macrophages) 
at the site of injury. The migrated MSCs 
secretes immunomodulatory factors 
that attenuate the inflammation as well 
as growth factors that stimulate the mo-
bilization of tissue-resident MSCs and 
promote chondrogenesis and hence 
chondrocyte replenishment. Compiled 
using information sourced from  Clark 
KC. et al, 2016 and Atta H. et al., 2016 
(42, 48).
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apoptosis, activating endogenous stem cell proliferation, 
differentiation and improvement of blood flow in joints 
(48). Therefore, the interplay between MSCs and the 
inflammatory immune factors is essential for  tissue 
repair and cartilage regeneration (Figure 3). 
CONCLUSION
Understanding the crosstalk between tissue-resident 
stem cells and damaged cartilages due to OA is 
important in ensuring timely and effective repair 
of the injured cartilage. At the initial step of OA 
pathophysiology, extensive injuries coupled with 
unbearable immunological/ inflammatory insults 
supersedes the reparative capability of tissue-resident 
stem cells. Thus, this review highlights the effect of local 
inflammation on the MSC function and suggest that 
treatment of the OA should be focused on correcting 
the proinflammatory status of damaged cartilage whilst 
elevating the regenerative ability of the cartilage through 
infusing of MSCs. Although MSCs are progenitors of 
the cartilage tissue, the hypothesis that third party 
MSCs’ differentiation is responsible for chondrocytes 
production is not fully supported in the clinical studies. 
Thus, it could be assumed that externally delivered MSCs 
enhance the regenerative potential of the tissue-resident 
stem cells and attenuates the inflammatory scenario of 
the affected joint to nurture the repair and regeneration 
processes.  
act by promoting the development of cartilage tissue 
precursor, fibroblasts and endothelial cells (31, 42).
The release of growth factors alone is not sufficient to 
induce tissue repair and regeneration, rather a conducive 
inflammation-free microenvironment is required; this 
may, however, be jeopardised by the pro-inflammatory 
milieu hallmarked in injured cartilage (46). Thus, 
the need to attenuate the “toxic” microenvironment 
is equally essential as to induce tissue repair and 
regeneration. It has been shown that MSCs as well 
secrete anti-inflammatory/ immunosuppressive agents 
such as Interleukin-10 (IL-10), Interleukin-1 receptor 
antagonist (IL-Ra), inducible nitric oxide synthase 
(iNOS), chemokine ligand 2 (CCL2), indoleamine 
2,3-dioxygenase (IDO), Semaphorin-3A, V-set domain-
containing T-cell activation inhibitor 1 (VTCNT1), 
human leukocyte antigen G (HLA-G), leukemia 
inhibitory factor (LIF), Galectin(s), heme oxygenase-1 
(HO-1), Interleukin-6 (IL-6), prostaglandin E2 (PGE2), 
programmed cell death 1 ligand1/2 (PD-L1/2), TNF-α 
stimulated gene/protein (TSG) and Fas ligand (FasL) 
(43, 47). It is important to note, however, that the afore-
mentioned anti-inflammatory cytokines and proteins 
produced by the MSCs are not exclusive to the MSCs 
and the different type of cytokines produced might vary 
upon the source and passage of external MSCs. The anti-
inflammatory/immunosuppressive factors act mainly 
by modulating the inflammatory response, inhibiting 
Figure 3: Interplay between MSCs, inflammatory cytokines and paracrine factors in cartilage tissue repair. The hC-MSCs move to the site of 
inflammatory injury in response to stimulation by inflammatory cytokines (TNF-α, IL-1α/β, and IFN-γ). The stimulated MSCs release paracrine 
factors (Ang-1, angiopoietin-1; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; FGF, fibroblast growth factor; VEGF, vascular 
endothelial growth factor; TGF-b, transforming growth factor b; HGF, hepatocyte growth factor; IGF, insulin growth factor-1; KGF, keratinocyte 
growth factor; EPO, erythropoietin; GDNF, glial cell line-derived neurotrophic factor; IL-8, interleukin-8 and SDF -1, stem cell-derived factor-1) 
as well as immunomodulatory factors (IL-10, Interleukin-10; IL-Ra, Interleukin-1 receptor antagonist; iNOS, inducible nitric oxide synthase; 
CCL2, chemokine ligand 2; IDO, indoleamine 2,3-dioxygenase; Semaphorin-3A; VTCNT1, V-set domain-containing T-cell activation inhibitor 
1; HLA-G, human leukocyte antigen G; LIF, leukemia inhibitory factor; Galectin(s); HO-1, heme oxygenase-1; IL-6, Interleukin-6; PGE2, pros-
taglandin E2; PD-L1/2, programmed cell death 1 ligand1/2; TSG, TNF-α stimulated gene/protein and FasL, Fas ligand). These factors’ concerted 
effect promotes trophic and regenerative processes which lead to healing and tissue repair. Compiled using information sourced from (42, 48).
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